Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Journal of Pediatric Gastroenterology and Nutrition · 2025
DOI: 10.1002/jpn3.12402 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Rasha Abi Radi Abou Jaoudeh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatrics and Adolescent Medicine, Cleveland Clinic Children's Center, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Pediatric Obesity. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Pediatric obesity, characterized by a body mass index (BMI) at or above the 95th percentile for age, affects a substantial number of children and adolescents worldwide. Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, represents a prominent hepatic manifestation of obesity and metabolic syndrome, emerging as the most prevalent hepatic disorder among pediatric patients and a significant contributor to liver transplantation in adults. The escalating prevalence of pediatric MASLD mirrors the alarming rise in childhood obesity rates over recent decades. While lifestyle modifications focusing on dietary changes and increased physical activity constitute the cornerstone of MASLD management, achieving and maintaining significant weight reduction remains challenging. Moreover, disease progression often persists despite standard‐of‐care interventions, warranting exploration into alternative therapeutic strategies. Pharmacological interventions, particularly, glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), have shown promise in addressing pediatric obesity and its associated comorbidities, including MASLD. Recent studies have demonstrated the efficacy of GLP‐1RA in inducing weight loss and improving liver enzyme levels, suggesting a potential role in halting disease progression, and reducing the risk of major adverse liver outcomes. This review provides a comprehensive overview of the current pharmacotherapy landscape for pediatric MASLD, with a focus on novel agents such as GLP‐1RA. Furthermore, the manuscript proposes a practical algorithm to assist in integrating GLP‐1RA into the clinical management of pediatric patients with obesity and MASLD. Despite promising results, further research is warranted to elucidate the long‐term efficacy and safety of GLP‐1RA in pediatric populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatrics and Adolescent Medicine, Cleveland Clinic Children's Center, Cleveland, Ohio, USA.
- Department of Pediatrics, University of California San Diego, La Jolla, California, USA.
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Rady Children's Hospital San Diego, San Diego, California, USA.
- Division of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Diabetes and Endocrinology, Duke University, Durham, North Carolina, USA.
- Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Sara Hassan
Förderung
- None
Zitieren
APA
Abou Jaoudeh, R. A. R., Hartmann, P., Olson, O., Gupta, O., Kumar, S., Ibrahim, S. H., Fawaz, R., Aqul, A., & Hassan, S. (2025). Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12402
Vancouver
Abou Jaoudeh RAR, Hartmann P, Olson O, Gupta O, Kumar S, Ibrahim SH, et al. Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.12402
BibTeX
@article{AbouJaoudeh2025,
author = {Abou Jaoudeh, Rasha Abi Radi and Hartmann, Phillipp and Olson, Ole and Gupta, Olga and Kumar, Seema and Ibrahim, Samar H and Fawaz, Rima and Aqul, Amal and Hassan, Sara},
title = {Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
doi = {10.1002/jpn3.12402}
}
EUVIMED